Makita Z, Radoff S, Rayfield E J, Yang Z, Skolnik E, Delaney V, Friedman E A, Cerami A, Vlassara H
Laboratory of Medical Biochemistry, Rockefeller University, New York, NY 10021.
N Engl J Med. 1991 Sep 19;325(12):836-42. doi: 10.1056/NEJM199109193251202.
Glucose reacts nonenzymatically with proteins in vivo, chemically forming covalently attached glucose-addition products and cross-links between proteins. The excessive accumulation of rearranged late-glucose-addition products, or advanced glycosylation end products (AGEs), is believed to contribute to the chronic complications of diabetes mellitus.
To elucidate the relation of AGEs to diabetic complications, we used a radioreceptor assay to measure serum and tissue AGEs in diabetic (Types I and Type II) and nondiabetic patients with different levels of renal function. Serum AGEs were measured as a low-molecular-weight (less than or equal to 10 kd) peptide fraction and a high-molecular-weight (greater than 10 kd) protein fraction.
The mean (+/- SD) AGE content of samples of arterial-wall collagen from 9 diabetic patients was significantly higher than that of samples from 18 nondiabetic patients (14.5 +/- 5.2 vs. 3.6 +/- 1.5 AGE units per milligram, P less than 0.001). Moreover, diabetic patients with end-stage renal disease had almost twice as much AGE in tissue as diabetic patients without renal disease (21.3 +/- 2.8 vs. 11.5 +/- 1.9 AGE units per milligram, P less than 0.001). The AGE levels in both serum fractions were elevated in the patients with diabetes, and the levels of AGE peptides correlated directly with serum creatinine (P less than 0.001) and inversely with creatinine clearance (P less than 0.005), suggesting that levels of AGE peptides increased with the severity of diabetic nephropathy. In six patients with diabetes who required hemodialysis, the levels of AGE peptides were five times higher than in eight normal subjects (82.8 +/- 9.4 vs. 15.6 +/- 3.4 AGE units per milliliter, P less than 0.001). In another group of diabetic patients the mean serum creatinine level, which decreased by 75 percent during a session of hemodialysis, whereas the level of AGE peptides decreased by only 24 percent. Serum levels of AGE peptides were normal in two patients with normal serum creatinine levels after renal transplantation.
AGEs accumulate at a faster-than-normal rate in arteries and the circulation of patients with diabetes; the increase in circulating AGE peptides parallels the severity of renal functional impairment in diabetic nephropathy.
葡萄糖在体内与蛋白质发生非酶反应,通过化学方式形成共价连接的葡萄糖加成产物以及蛋白质之间的交联。重排后的晚期葡萄糖加成产物,即晚期糖基化终末产物(AGEs)过度积累,被认为会导致糖尿病的慢性并发症。
为了阐明AGEs与糖尿病并发症之间的关系,我们使用放射受体测定法来测量患有不同肾功能水平的糖尿病(I型和II型)及非糖尿病患者的血清和组织中的AGEs。血清AGEs被测定为低分子量(小于或等于10kd)肽段部分和高分子量(大于10kd)蛋白质部分。
9名糖尿病患者动脉壁胶原样本的平均(±标准差)AGE含量显著高于18名非糖尿病患者的样本(每毫克14.5±5.2个AGE单位对3.6±1.5个AGE单位,P<0.001)。此外,终末期肾病的糖尿病患者组织中的AGE含量几乎是非肾病糖尿病患者的两倍(每毫克21.3±2.8个AGE单位对11.5±1.9个AGE单位,P<0.001)。糖尿病患者血清两个部分的AGE水平均升高,AGE肽水平与血清肌酐直接相关(P<0.001),与肌酐清除率呈负相关(P<0.005),这表明AGE肽水平随糖尿病肾病的严重程度增加而升高。在6名需要血液透析的糖尿病患者中,AGE肽水平比8名正常受试者高5倍(每毫升82.8±9.4个AGE单位对15.6±3.4个AGE单位,P<0.001)。在另一组糖尿病患者中,平均血清肌酐水平在一次血液透析过程中下降了75%,而AGE肽水平仅下降了24%。肾移植后血清肌酐水平正常的两名患者血清AGE肽水平正常。
糖尿病患者动脉和循环中AGEs的积累速度高于正常水平;循环中AGE肽的增加与糖尿病肾病中肾功能损害的严重程度平行。